Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

LifeScan glucose meter recall

This article was originally published in The Gray Sheet

Executive Summary

Users of Johnson & Johnson's OneTouch Ultra, OneTouch FastTake and InDuo need not return the blood glucose monitors despite a Class I recall affecting the devices, FDA clarifies in a FDL-1public message on its website June 13. The monitors permit users to "accidentally change the unit of measure" by dropping the instrument or subjecting it to similar trauma. When J&J/LifeScan became aware of the problem earlier this year, it suspended shipments and notified users. "FDA believes that most patients are capable of understanding and following" the firm's instructions, the agency states, noting that LifeScan now offers alternative devices to curb test misinterpretation. LifeScan reps met with CDRH Director Dan Schultz and Office of In Vitro Diagnostic Devices Evaluation & Safety officials June 3...

Latest Headlines
See All
UsernamePublicRestriction

Register

MT022276

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel